How did you decide to participate in the Biomapas Academy?
The first thing that caught my attention was the Biomapas Academy poster hanging on my university’s bulletin board. Shortly afterwards, the faculty management shared Biomapas’ invitation to register for the first Biomapas Academy. I wanted to learn more about this company, so I decided to take my chances and apply to the Academy. I was thrilled when I received a call with the happy news that I had successfully passed the selection process and was invited to attend the Academy.
What was your experience during the three months?
I listened to many interesting lectures, during which we got to know the company and its areas of activity. We listened to lectures on clinical trials and their organization, pharmacovigilance, regulatory affairs, bioethics, drug registration, and more. I believe that the knowledge gained at the Academy is valuable and helpful for all participants of the Academy and their future careers.
What did the future hold for you after the Academy?
I mainly was interested in pharmacovigilance, so we agreed on an internship in this department during the summer. Interesting fact: the first Biomapas poster I saw was about pharmacovigilance! And the best thing is that after the internship, I was able to join and become a part of this great team. I am happy to be here and to learn from real professionals in this field.
What would you say to the future participants?
I want to encourage everyone who is thinking about participating in the Biomapas Academy. Being at the Academy is exciting and worthwhile. By joining the Academy, you will broaden your horizons, learn from global professionals, improve your life sciences knowledge, and gain valuable experience. I wish good luck to all participants. See you soon at Biomapas!
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
How the right CRO site network partnership accelerates clinical trials
Explore how these partnerships work in practice, why Sponsors in Europe increasingly prefer them, and the regulatory push behind the shift.
MENA PV Landscape – Key Updates & Inspection Trends
Timely insights on the evolving Pharmacovigilance landscape in the MENA region.
Navigating Pharmacovigilance Requirements in LATAM
Insights into the evolving Pharmacovigilance landscape across the LATAM region.
Centralized Pharmacovigilance: Ensuring Compliance and Efficiency Across Global Markets
This article explores the benefits of centralized pharmacovigilance outsourcing and the single-provider model.
Diversity in Clinical Trials: A European Perspective on Global Progress and Strategies
Discover insights on diversity in clinical trials, regulatory compliance to inclusion, the European approach, and trial design innovations.
Biomapas Welcomes David Passov as Chief Executive Officer
Press Release Biomapas Welcomes David Passov as Chief Executive OfficerWe are pleased to announce the appointment of David Passov, MBA, as our new Chief Executive Officer, effective 21st February 2025. David Passov brings extensive leadership experience in life...
How functional service provision (FSP) helps biotech companies streamline clinical trial operations
In recent years, biotech companies face pressure to optimize clinical trial operations while managing costs, ensuring regulatory compliance, and maintaining flexibility. This is where Functional Service Provision (FSP) comes in. FSP offeres a scalable, flexible...
Functional Service Provision As Smarter Approach to Clinical Trial Execution
For biotech and pharmaceutical companies, the challenge isn’t just innovation but execution too. Functional Service Provision (FSP) enables organizations to optimize clinical trials without the bottlenecks of traditional outsourcing. As competition intensifies and...
Pharmacovigilance Auditing: Understanding the Process and Maximizing Its Benefits
Discover how pharmacovigilance audits go beyond compliance to uncover hidden risks, drive improvement, and ensure every patient gets the safest treatment possible.
Diversity in Clinical Trials: A European Perspective on Global Progress and Strategies
In light of recent developments, we must recognise that diversity in clinical trials is not just a buzzword anymore, it is a key priority. Yet, with varying perspectives from regulatory agencies worldwide, and an industry still unaligned on the best approaches, there...
